SCHEDULE 13G/A: Nantahala Capital Management Discloses Significant 38% Stake in Eagle Pharmaceuticals

Nantahala Capital Management, along with its principals Wilmot B. Harkey and Daniel Mack, has reported a substantial 38.078% beneficial ownership stake in Eagle Pharmaceuticals, Inc. as of February 16, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Eagle Pharmaceuticals, Inc.
• As of February 16, 2025, the Reporting Persons collectively beneficially own 4,945,209 shares of Eagle Pharmaceuticals' Common Stock.
• This ownership represents 38.078% of the total outstanding shares of the class.
• Nantahala Capital Management, LLC is identified as an investment adviser and hedge fund, while Messrs. Harkey and Mack are its managing members and citizens of the United States.
• The shares are held by funds and separately managed accounts under Nantahala's control, with shared voting and dispositive power over all 4,945,209 shares.
• Two specific funds advised by Nantahala, NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP and BLACKWELL PARTNERS LLC SERIES A, each hold more than five percent of the outstanding common stock beneficially owned by Nantahala.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: Neutral, as this is a factual report of beneficial ownership and does not contain performance or forward-looking statements that would indicate positive or negative sentiment.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing reflects a significant passive investment by an institutional investor in a publicly traded pharmaceutical company. Such large stakes can indicate a long-term investment thesis by the fund, but the filing itself does not provide details on industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The disclosure of a significant 38.078% stake by Nantahala Capital Management indicates a concentrated ownership structure, which could influence future corporate governance matters, strategic decisions, or potential M&A activities. While the filing states the shares were not acquired for control, such a large stake inherently carries influence.

Key Dates

Keywords

Eagle Pharmaceuticals, Nantahala Capital Management, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Investment Adviser, Shareholder Stake